New registry to track PSMA therapy in 500 men with advanced prostate cancer

NCT ID NCT04769817

Ongoing Knowledge-focused Sponsor: Peter MacCallum Cancer Centre, Australia Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This observational registry will follow 500 men with metastatic castration-resistant prostate cancer who are receiving PSMA theranostics (177Lu-PSMA) as part of their standard care. Researchers will track how well the treatment lowers PSA levels and monitor any serious side effects. The goal is to gather real-world data on outcomes and safety to guide future use.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: 177Lu-PSMA
What this could lead to: If successful, this registry could provide real-world evidence on how well PSMA theranostics work and their safety in men with advanced prostate cancer.
What could go wrong: This is an observational registry, not a controlled trial, so results may be influenced by patient selection and other treatments. It does not test a new therapy directly.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma metastatic prostate carcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PROSTATE CANCER

Contacts and locations

Locations

Peter MacCallum Cancer Centre

Melbourne, Victoria, 3000, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.